Talking Points: Recent Episodes
TCTMD
A selection of the best interviews conducted by physician leaders and recorded at cardiology conferences around the globe.
Pavel Osmancik and C. Michael Gibson discuss whether catheter ablation is superior to risk factor modification with antiarrythmic drugs for the treatment of AF.
How does discontinuing beta-blockers after MI affect outcomes in patients without HF? Dan Atar and C. Michael Gibson break it down.
In one of the most thought-provoking sessions at New York Valves 2026, Michael Mack and Roxana Mehran moderate a panel discussion looking at the future of TAVI from all angles.
Ruben de Winter and C. Michael Gibson compare clinical outcomes of native vessel versus SVG PCI for patients with prior CABG.
Christian M. Spaulding and C. Michael Gibson look at the 1-year results from the study comparing sirolimus-eluting DCB with DES for de novo coronary lesions.
Paul Burton and C. Michael Gibson discuss the effects of adding evolocumab for patients at high risk for CV events but without prior MI or stroke.
Amrish Deshmukh talks to C. Michael Gibson about the use of metformin as an adjunctive therapy to catheter ablation of AF.
How has the pharmacotherapy for STEMI changed over the past 46 years? Ginger Jiang and C. Michael Gibson discuss treating patients with zalunfiban at first medical contact.
Colin Berry and C. Michael Gibson discuss whether stress CMR imaging is helpful in patients with angina and no obstructive CAD.
Sripal Bangalore and C. Michael Gibson discuss whether ticagrelor is noninferior to prasugrel in patients with diabetes and multivessel CAD undergoing PCI.
C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
Mamas Mamas, Nieves Gonzalo, and Erick Schampaert take a look at the latest guidelines for chronic coronary syndromes and how they relate to complex PCI.
Thomas Crawford meets with C. Michael Gibson to discuss the role of reconditioned pacemakers in low- and middle-income countries.
Mamas Mamas, Birgitte Krogsgaard Andersen, and Niels Ramsing Holm discuss QFR versus FFR for guiding resvascularization in patients with coronary stenoses.
C. Michael Gibson talks to Katherine Tuttle about semaglutide's positive effects in patients with diabetes and chronic kidney disease.
James Benenati, Robert Lookstein, and Rachel Rosovsky discuss the STORM-PE trial, the first-of-its-kind RCT for acute intermediate-high risk pulmonary embolism (PE).
For patients with aortic stenosis, is earlier intervention beneficial? Mamas Mamas, Philippe Généreux, Nicolas Van Mieghem, and Bernard Prendergast discuss.
Mamas Mamas and Gi-byoung Nam discuss edoxaban monotherapy in patients with high-risk AF and stable CAD.
Ajay Kirtane and C. Michael Gibson discuss how orbital atherectomy compares with balloon angioplasty for severely calcified coronary arteries before DES implantation.
Does long-term colchicine benefit patients after acute MI? C. Michael Gibson and Sanjit Jolly discuss.
Mamas Mamas talks to Jacob Thomsen Lønborg about how PCI affects outcomes for patients with stable CAD undergoing TAVI.
Transcatheter devices are new to the heart failure (HF) community and treatment armamentarium for severe MR. This discussion focuses on the impact of transcatheter devices on HF patients and current barriers faced by referring specialists.
Johanne Silvain, Gilles Montalescot, and C. Michael Gibson discuss the effects of beta-blocker interruption in post-MI patients.
Patient selection is important for transcatheter interventions and impacts result success. This discussion focuses on defining what treatment goals should be, limitations of current interventions, and identifying appropriate transcatheter patients.
Paul Ridker and C. Michael Gibson discuss 30-year data hinting at how three modifiable factors—LDL, hs-CRP, and Lp(a)—might be leveraged to reduce long-term risk. 06f763f0-76e5-11f0-bb7c-8557ae1d8a8b
Clinical trials face challenges with variability in echo images, protocol adherence, and data quality. This discussion focuses on strategies to improve trial integrity, operational efficiency, and regulatory approval of transcatheter devices.
The Intrepid TMVR system just released 2-year transfemoral EFS outcomes at NY Valves. This discussion provides a deeper dive into what this data means for the Intrepid mitral program and perspectives on the transcatheter landscape.
Renate Schnabel, Ruben Casado Arroyo, and Mamas Mamas discuss the atrial fibrillation recommendations unveiled at ESC Congress 2024.
Dipak Kotecha talks to C. Michael Gibson about whether educating healthcare providers on rhythm-control therapy affects guideline adherence and stroke outcomes.
Gi-Byoung Nam, Duk-Woo Park, and C. Michael Gibson weigh edoxaban monotherapy vs dual antithrombotic therapy for patients with AF and stable coronary artery disease.
Mamas Mamas talks to Tesfaye Telila about the landscape of acute coronary care in Ethiopa, where just a few dozen cardiologists contend with a population of 120 million people.
Should we stop anticoagulation therapy before TAVI in patients with aortic stenosis? Dirk-Jan van Ginkel and C. Michael Gibson discuss.
Vijay Kunadian talks to C. Michael Gibson about using an invasive or conservative strategy for older patients with NSTEMI.
Troels Yndigegn, Sripal Bangalore, and Mamas Mamas discuss whether beta-blockers still benefit patients with acute MI and preserved ejection fraction.
Gianluca Campo and C. Michael Gibson compare complete versus culprit-only revascularization in older STEMI patients.
David Ferreira talks to C. Michael Gibson about the latest data showing patients don't need to fast ahead of cardiac catheterization.
Mamas Mamas, Stefan Anker, and Volker Rudolph talk about their studies of MitraClip for functional MR in patients with heart failure.
Javed Butler and C. Michael Gibson discuss the trial testing early empagliflozin after acute MI.
Talking with C. Michael Gibson, David Austin reviews the phase III trial of enalapril for anthracycline-induced cardiotoxicity in lymphoma and breast cancer patients.
Rasha Al-Lamee and Michael Foley sit down with Mamas Mamas to discuss data on an implantable coronary sinus reducer that can ease symptoms in patients with refractory angina.
Looking at the REVIVED-BCIS2 results, Divaka Perera and C. Michael Gibson discuss the relationship between myocardial viability, PCI, and outcomes.
Iulia Iatan talks to C. Michael Gibson about how a low-carbohydrate, high-protein diet can increase plasma lipid levels and cardiovascular risk.
Steven Nissen and C. Michael Gibson discuss using bempedoic acid to reduce MACE in statin-intolerant patients with high cardiovascular risk.
Pooling data from the PROMINENT, REDUCE-IT, and STRENGTH trials, Paul Ridker and C. Michael Gibson discuss the residual inflammatory risks for patients treated with statins.
Béla Merkely and C. Michael Gibson discuss the results of a CRT-D upgrade versus ICD alone for HFrEF patients with right ventricular pacing.
Robert Mentz and C. Michael Gibson discuss the latest trial to address whether iron supplementation, this time with ferric carboxymaltose, improves outcomes for patients with HF and iron deficiency.
Simone Biscaglia and C. Michael Gibson discuss physiology-guided complete revascularization versus culprit-only PCI for elderly patients with acute MI.
Holger Thiele and C. Michael Gibson discuss the impact of VA-ECMO on patients with acute MI and advanced cardiogenic shock.
Masahiro Natsuaki and C. Michael Gibson discuss this latest randomized comparison of prasugrel monotherapy and DAPT with aspirin for patients undergoing PCI.
Ziad Ali and C. Michael Gibson take a deeper dive into this comparison of OCT- and angiography-guided PCI.
Gregg Stone and C. Michael Gibson discuss an updated meta-analysis addressing intravascular imaging in DES implantation.
Julian Gillmore and C. Michael Gibson discuss the efficacy of acoramidis for patients with transthyretin amyloid cardiomyopathy.
Vivek Reddy and C. Michael Gibson compare pulsed field ablation versus thermal ablation for patients with paroxysmal atrial fibrillation.
Mathieu Kerneis and C. Michael Gibson compare outcomes of patients treated with anakinra, a new therapy for acute myocarditis, or placebo.
Dan Jones and C. Michael Gibson discuss whether inorganic nitrate reduces contrast-induced nephropathy after angiography in ACS patients.
Zachary Cox and C. Michael Gibson discuss whether early dapagliflozin initiation is safe and effective for patients with acute heart failure.
Shaoping Nie, Gilles Montalescot, and C. Michael Gibson discuss prolonged anticoagulation after primary PCI for patients with MI.
Michael J. Reardon and C. Michael Gibson discuss the trial's 4-year results in low-surgical-risk patients with severe aortic stenosis randomized to self-expanding TAVI or SAVR.
Robert W. Yeh and C. Michael Gibson discuss the primary outcomes of this eagerly awaited trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis.
Susheel K. Kodali and C. Michael Gibson discuss transcatheter tricuspid valve replacement in patients with severe tricuspid regurgitation.
Josep Rodés-Cabau and C. Michael Gibson discuss the benefits of TAVI versus SAVR in patients with severe aortic stenosis and small aortic annuli.
A. Michael Lincoff and C. Michael Gibson discuss the cardiovascular impact of semaglutide in patients with overweight or obesity but without diabetes.
Jeffrey Carson and Serge Korjian discuss restrictive versus liberal blood transfusion in patients with MI and anemia.
Christopher Rajkumar, Rasha Al-Lamee, and C. Michael Gibson discuss this randomized trial of PCI versus a placebo procedure for stable angina.
Mandeep Mehra and C. Michael Gibson discuss whether or not aspirin is needed for patients with left ventricular assist devices in advanced heart failure.
Christian T. Ruff and C. Michael Gibson discuss the primary results of a randomized trial testing the efficacy of abelacimab versus rivaroxaban for stroke prevention in atrial fibrillation.
Andrew Bellinger, Sek Kathiresan, and C. Michael Gibson talk about the phase 1b trial of what investigators hope may be a one-time genetic fix for hyperlipidemia.
Steven Nissen and C. Michael Gibson discuss the efficacy and safety of lepodisiran, an extended duration short-interfering RNA meant to reduce lipoprotein (a).
Paul Ridker and C. Michael Gibson discuss whether residual inflammatory risk or residual cholesterol risk is a more effective predictor of CV events among patients treated with statins.
Mike Sharma and C. Michael Gibson discuss managing acute thromboembolic events in secondary stroke using antithrombotic treatment with factor XIa inhibition.
Axel Bauer and C. Michael Gibson talk about whether smartphone-based screening can effectively detect atrial fibrillation in elderly, at-risk patients.
Ganesan Karthikeyan and C. Michael Gibson compare the efficacy of rivaroxaban versus vitamin K agonists for patients with rheumatic heart disease associated atrial fibrillation
Joo-Yong Hahn and C. Michael Gibson compare FFR with angiography-guided PCI for patients with acute myocardial infarction and multivessel disease.
Marco Valgimigli and C. Michael Gibson discuss the long-term follow-up results from MASTER DAPT, which compared the outcomes of high bleeding risk patients randomized to either abbreviated or standard antiplatelet therapy.
Marco Valgimigli and C. Michael Gibson discuss the PANTHER trial, which compared P2Y12 inhibitor monotherapy with aspririn monotherapy in patients with coronary artery disease.
Giuseppe Gargiulo and C. Michael Gibson discuss whether the choice of radial or femoral artery access impacts the risk of mortality and major bleeding for patients undergoing coronary procedures.
Sanjit Jolly and C. Michael Gibson discuss if colchicine and rivaroxaban plus aspirin can slow disease progression in patients hospitalized with COVID-19.
Milind Desai and C. Michael Gibson compare the results of mavacamten for severe obstructive hypertropic cardiomyopathy with the typical treatments of surgical septal myectomy or alcohol ablation.
Justin Ezekowitz and C. Michael Gibson look at a sodium-reducing dietary intervention and its effects on patients with HF.
Shamir Mehta and C. Michael Gibson discuss how complete revascularization affects angina-related quality of life in patients with STEMI.
Tijn Jansen, Suzette Elias-Smale, and C. Michael Gibson discuss whether diltiazem improves coronary vasomotor dysfunction in patients with angina and nonobstructive coronary artery disease.
Mark Loeb and C. Michael Gibson discuss whether the influenza vaccine can reduce adverse vascular events among patients with HF.
Gregory Lewis and C. Michael Gibson discuss how omecamtiv mecarbil affects exercise tolerance in patients with chronic HFrEF.
Javed Butler and C. Michael Gibson discuss using patiromer to manage hyperkalemia in patients with HFrEF who are taking RAAS inhibitors.
Florian Rader and C. Michael Gibson look at cumulative outcomes for patients with obstructive hypertrophic cardiomyopathy treated with mavacamten.
Manesh Patel and C. Michael Gibson discuss the results of a phase II trial comparing the safety profiles of asundexian versus apixaban in patients with atrial fibrillation.
Daniel Sessler and C. Michael Gibson compare myocardial injury rates following mild hypothermia versus aggressive warming during noncardiac surgery.
Duk-Woo Park and C. Michael Gibson discuss edoxaban vs dual antiplatelet therapy for valve thrombosis and cerebral thromboembolism after TAVI.
Bon-Kwon Koo and C. Michael Gibson compare the efficacy of FFR-guided and IV ultrasound-guided PCI for coronary artery stenosis.
Marie-Sophie de Koning and C. Michael Gibson discuss whether the use of sodium thiosulfate after STEMI helps preserve cardiac function.
Felix Mahfoud and C. Michael Gibson examine the efficacy of renal denervation for long-term BP reduction in patients taking antihypertensive medication.
Paul Ridker and C. Michael Gibson discuss a secondary analysis from CANTOS looking at residual inflammatory and cholesterol risks based on chronic kidney disease status.
Michael Mack and C. Michael Gibson discuss a novel method for extracting antithrombotics from the blood during CABG.
C. Michael Gibson and Jesper Hastrup Svendsen discuss the use of implantable loop recorders to prevent stroke in AF.
C. Michael Gibson and George Dangas discuss edoxaban vs vitamin K antagonists after TAVI in patients with atrial fibrillation.
C. Michael Gibson and Dhanunjaya Lakkireddy discuss device success and thrombus risk in Amulet versus Watchman for LAA closure.
C. Michael Gibson and Timothy Henry discuss key updates to the SCAI SHOCK classifications.
C. Michael Gibson and Renato Lopes discuss extended DOAC prophylaxis in medically ill, hospitalized patients with COVID-19.
C. Michael Gibson and Nicholas Curzen discuss whether routine pressure-wire assessment influences the use of coronary angiography for diagnosing chest pain.
C. Michael Gibson and David Cohen discuss cost implications of this TAVI versus SAVR randomized trial.
C. Michael Gibson and Ole Fröbert discuss the potential for influenza vaccination in post-MI patients.
C. Michael Gibson and Wan Azman Wan Ahmad discuss a sirolimus-versus a paclitaxel-coated balloon in de novo coronary lesions.
C. Michael Gibson and Stefan Anker discuss the effects of empagliflozin on CV death and HF hospitalizations in patients with HFpEF, with and without diabetes.
C. Michael Gibson and Matthias Götberg review 5-year findings after iFR- versus FFR-guided PCI.
Renato Lopes and C. Michael Gibson discuss PRONOUNCE comparing the cardiovascular safety of degarelix vs. leuprolide in patients with advanced prostate cancer and CVD.
Desai and Anahita Dua discuss highlights from a CME program on reducing thrombosis risks in patients with PAD post-revascularization. Claim credit: https://bit.ly/3QTpBt6. Supported by an educational grant from Janssen Scientific Affairs, LLC.
C. Michael Gibson and Steffen Desch discuss whether immediate angiography is warranted after out-of-hospital cardiac arrest.
C. Michael Gibson and David Kandzari discuss PCI outcomes among patients at prohibitive risk for CABG.
C. Michael Gibson and Marco Valgimigli discuss dual antiplatelet therapy after coronary stenting in high-bleeding-risk patients.
C. Michael Gibson, Haibo Jia, and Jingbo Hou discuss whether OCT guidance could cut stent use in STEMI without plaque rupture.
C. Michael Gibson and Douglas Mann discuss sacubitril/valsartan in patients with advanced HFrEF.
C. Michael Gibson and Pavel Osmancik review 3-year results with LAA closure versus a DOAC for patients with atrial fibrillation.
C. Michael Gibson and Pieter C. Smits review outcomes in high-bleeding-risk patients also at high risk for thrombotic events who were randomized to abbreviated DAPT.
C. Michael Gibson discusses aspirin dosing and long-term effectivness with Schuyler Jones and Greg Merritt.
C. Michael Gibson and Kreton Mavromatis discuss how completeness of revascularization impacts quality of life in stable ischemic heart disease patients.
C. Michael Gibson and Steven Nissen discuss the link between omega-3 fatty acid levels and MACE in patients with high cardiovascular risk.
C. Michael Gibson and Kreton Mavromatis discuss how completeness of revascularization impacts quality of life in stable ischemic heart disease patients.
C. Michael Gibson and Carolyn Lam discuss key updates to the European heart failure guidelines and how best to initiate medications to optimize outcomes.
C. Michael Gibson, Jean-Philippe Collet, and Gilles Montalescot and discuss apixiban after TAVI in the Atlantis trial.
C. Michael Gibson and Firas Zahr discuss 30-day outcomes following transfemoral transseptal TMVR.
Junjie Zhang and C. Michael Gibson discuss 3-year outcomes after IVUS- versus angiography-guided DES implantation.
Gregg Stone and C. Michael Gibson discuss a randomized trial examining interventional treatment of vulnerable plaques.
Robert Byrne and C. Michael Gibson discuss a randomized trial of a thromboresistant Polyzene F-coated stent with 14-day DAPT in high-bleeding-risk patients.
Otavio Berwanger and C. Michael Gibson discuss rivaroxaban versus warfarin in patients with bioprosthetic mitral valves and atrial fibrillation or flutter.
Corrado Tamburino and C. Michael Gibson discuss a randomized trial of two self-expanding TAVR bioprostheses.
Dean Kereiakes and C. Michael Gibson discuss intravascular lithotripsy for the treatment of severe coronary calcification.
Byeong-Keuk Kim and C. Michael Gibson discuss a randomized trial of ticagrelor monotherapy versus ticagrelor with aspirin in STEMI.
Georgios Vlachojannis and C. Michael Gibson discuss a randomized trial of prehospital crushed versus uncrushed prasugrel in STEMI.
Jeffrey Moses and C. Michael Gibson discuss a randomized trial of cerebral embolic protection during TAVR.
Salim Yusuf and C. Michael Gibson discuss aspirin alone and in combination with a polypill for CVD primary prevention.
Philipp Lurz and C. Michael Gibson discuss a randomized trial of ASD closure after TMVr.
Roxana Mehran and C. Michael Gibson discuss 3-month and 1-month DAPT after everolimus-eluting stents in high-bleeding-risk patients.
Steven Steinhubl and C. Michael Gibson discuss 3-year outcomes in a nationwide, randomized, pragmatic clinical trial of A-fib screening.
Damien Collison and C. Michael Gibson discuss a randomized trial of physiology-guided PCI optimization.
A. Michael Lincoff and C. Michael Gibson discuss CV outcomes with omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia.
A. Michael Lincoff and C. Michael Gibson discuss CV outcomes with omega-3 carboxylic acids in patients with high vascular risk and atherogenic dyslipidemia.
Dean Kereiakes and C. MIchael Gibson discuss a randomized trial of a novel, ultra-low-profile fixed-wire DES.
Robert Harrington and C. Michael Gibson discuss the registry's design, implementation, and initial results.
Ehrin Armstrong and C. Michael Gibson discuss a randomized, dose-escalation trial of temsirolimus adventitial delivery below the knee.
Iacopo Olivotto and C. Michael Gibson discuss mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy.
C. Michael Gibson and Catalin Toma discuss acute hemodynamic improvement with percutaneous mechanical thrombectomy in a real-world pulmonary embolism population.
Burkert Pieske and C. Michael Gibson discuss sacubitril/valsartan versus individualized RAAS blockade in HFpEF.
Pierre-Marie Roy and C. Michael Gibson discuss hospitalization or outpatient management of PE.
Paulus Kirchhof and C. Michael Gibson discuss early rhythm control therapy in patients with atrial fibrillation.
Kazem Rahimi and C. Michael Gibson discuss BP-lowering for prevention of cardiovascular events.
Dr. Jan Cornel and Dr. C. Michael Gibson Discuss: LoDoCo2 Low-Dose Colchicine in Coronary Disease.
C. Michael Gibson and Jorn Brouwer discuss aspirin with or without clopidogrel after transcatheter aortic valve replacement.
C. Michael GIbson and Milton Packer Discuss empagliflozin in heart failure with reduced ejection fraction.
C. Michael Gibson and Steven Goldberg discuss REDUCE-FMR and sham-controlled trials in MV repair.
C. Michael Gibson and Vinod Thourani discuss 5-year outcomes in this randomized trial of TAVR vs SAVR in intermediate-risk patients.
Suzanne Baron and C. Michael Gibson discuss important new details from these two structural heart disease trials.
Roxana Mehran brings C. Michael Gibson up to speed on a campaign to promote talent in medicine by offering professional opportunities to female physicians.
Usman Baber, who led this thrombogenicity substudy, walks C. Michael Gibson through the key findings.
What are the respective values of FFR and OCT in guiding revascularization? C. Michael Gibson gets a primer from Francesco Burzotta.
C. Michael Gibson connects with Sameer Mehta and Francisco Fernandez to hear how new tech is poised to disrupt medical care.
Maurizio Taramasso walks C. Michael Gibson through randomized data focused on tricuspid valve disease.
Vinay Badhwar discusses new data from the STS Registry addressing volume/outcome relationships for mitral valve surgery.
C. Michael Gibsons sits down with Carlo Briguori to discuss the REMEDIAL III trial results.
Samir Kapadia, Horst Sievert, and C. Michael Gibson discuss this randomized sham-controlled trial of the Carillon device.
C. Michael Gibson and Dean Kereiakes discuss the first human use of RUC-4, designed for STEMI point-of-care treatment.
C. Michael Gibson speaks with Gregg Stone about EXCEL: 5-Year Outcomes From a Randomized Trial of PCI vs. CABG in Patients With Left Main Coronary Artery Disease.
C. Michael Gibson speaks with Michael Mack about the COAPT Trial 3-year outcomes and results.
C. Michael Gibson speaks with Raj Makkar about PARTNER 3 Low-Risk Computed Tomography Substudy: Subclinical Leaflet Thrombosis in Transcatheter and Surgical Bioprosthetic Valves
C. Michael Gibson speaks with Kenneth Ouriel about LEVANT: 5-Year Outcomes From Three Randomized Trials of Percutaneous Angioplasty With vs. Without a Drug-Coated Balloon in Patients With Femoropopliteal Arterial Disease
C. Michael Gibson sits down with Horst Sievert to learn more about the REDUCE-FMR trial.
C. Michael Gibson learns more about Annapoorna Kini's work and why the field needs female role models.
C. Michael Gibson and Tom Ford discuss the potential for finding and treating patients with ANOCA.
C. Michael Gibson and David Cohen discuss adding years to life and adding life to years with the MitraClip.
C. Michael Gibson and Junjie Zhang discuss ULTIMATE: A Randomized Trial of Intravascular Ultrasound Guidance of Coronary Drug-Eluting Stent Implantation in an All-Comers Patient Population.
C. Michael Gibson and Holger Thiele take a deep dive into a head-to-head trial of TAVR devices that also considered general versus local anesthesia.
C. Michael Gibson talks with Patrick Serruys about, TALENT: A Randomized Trial Evaluating an Ultra-Thin Strut Bioresorbable Polymer-Based Coronary Drug-Eluting Stent in an All-Comers Patient Population."
Does timing of an atorvastatin loading dose make a difference in PCI for ACS? C. Michael Gibson and Renato Lopes discuss.
C. Michael Gibson, Kenneth Rosenfield, and Robert Lookstein discuss the way forward for PERT.
C. Michael Gibson and Pieter Stella discuss ReCre8, which evaluated a polymer-free DES in an all-comers population.
What do you get when you combine Twitter and a textbook? C. Michael Gibson talks with Michael Savage and David Fischman.
C. Michael Gibson talks to William Gray about IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions.
C. Michael Gibson speaks with Dominick Angiolillo about the 2018 North American Consensus Statement for Atrial Fibrilation Patients Undergoing PCI.
Early results with a new device being developed for transcatheter MV replacement are promising, Paul Sorajja tells C. Michael Gibson.
TRACER: 6-Month Outcomes of Transcatheter MV Neochordal Repair in Patients With Severe Primary Mitral Regurgitation
Dr. C. Michael Gibson talks to Dr. David W. M. Muller about TENDYNE: 1-Year Outcomes of Transcatheter MV Replacement in Patients With Severe Mitral Regurgitation
Dr. C. Michael Gisbon talks to Dr. Shao-Liang Chen about the DKCRUSH-V: A Randomized Trial of Double Kissing Crush vs Provisional Stenting for Treatment of Distal Left Main Bifurcation Lesions.
Listen to C. Michael Gibson in conversation with Giora Weisz. Color: A Multicenter Registry Looking at Lipid-Rich Plaque & 2-Year Outcomes After Stenting
C. Michael Gibson discusses health-status benefits in intermediate-risk patients treated with surgical or transcatheter aortic valve replacement.
C. Michael Gibson speaks with David Hildick-Smith about left atrial closure devices for stroke prevention.